These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 32244385)

  • 1. Antiproliferative and Antimigration Activities of Fluoro-Neplanocin A via Inhibition of Histone H3 Methylation in Triple-Negative Breast Cancer.
    Byun WS; Kim WK; Yoon JS; Jarhad DB; Jeong LS; Lee SK
    Biomolecules; 2020 Mar; 10(4):. PubMed ID: 32244385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of DOT1L by Half-Selenopsammaplin A Analogs Suppresses Tumor Growth and EMT-Mediated Metastasis in Triple-Negative Breast Cancer.
    Byun WS; Lee GH; Park HG; Lee SK
    Pharmaceuticals (Basel); 2020 Dec; 14(1):. PubMed ID: 33379275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Histone Methyltransferase DOT1L by a Novel Psammaplin A Analog Inhibits Growth and Metastasis of Triple-Negative Breast Cancer.
    Byun WS; Kim WK; Han HJ; Chung HJ; Jang K; Kim HS; Kim S; Kim D; Bae ES; Park S; Lee J; Park HG; Lee SK
    Mol Ther Oncolytics; 2019 Dec; 15():140-152. PubMed ID: 31720371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer.
    Yang L; Lei Q; Li L; Yang J; Dong Z; Cui H
    Clin Epigenetics; 2019 Dec; 11(1):199. PubMed ID: 31888761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer.
    Zhang L; Deng L; Chen F; Yao Y; Wu B; Wei L; Mo Q; Song Y
    Oncotarget; 2014 Nov; 5(21):10665-77. PubMed ID: 25359765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.
    Anbalagan M; Sheng M; Fleischer B; Zhang Y; Gao Y; Hoang V; Matossian M; Burks HE; Burow ME; Collins-Burow BM; Hangauer D; Rowan BG
    Mol Cancer Res; 2017 Nov; 15(11):1491-1502. PubMed ID: 28751463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Vitamin D Analog, MART-10, Attenuates Triple Negative Breast Cancer Cells Metastatic Potential.
    Chiang KC; Yeh TS; Chen SC; Pang JH; Yeh CN; Hsu JT; Chen LW; Kuo SF; Takano M; Kittaka A; Chen TC; Sun CC; Juang HH
    Int J Mol Sci; 2016 Apr; 17(4):. PubMed ID: 27110769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. UNC0638, a G9a inhibitor, suppresses epithelial‑mesenchymal transition‑mediated cellular migration and invasion in triple negative breast cancer.
    Liu XR; Zhou LH; Hu JX; Liu LM; Wan HP; Zhang XQ
    Mol Med Rep; 2018 Feb; 17(2):2239-2244. PubMed ID: 29207160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling.
    Chen Y; Chen ZY; Chen L; Zhang JY; Fu LY; Tao L; Zhang Y; Hu XX; Shen XC
    Biochem Pharmacol; 2019 Aug; 166():33-45. PubMed ID: 31071331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
    Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
    Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological activity of selenopsammaplin A and its analogues as antitumor agents with DOT1L inhibitory activity.
    Ju Han H; Sub Byun W; Ho Lee G; Kyung Kim W; Jang K; Yang S; Yang J; Woo Ha M; Hong S; Lee J; Shin J; Bong Oh K; Kook Lee S; Park HG
    Bioorg Med Chem; 2021 Apr; 35():116072. PubMed ID: 33636429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KMT2D-mediated H3K4me1 recruits YBX1 to facilitate triple-negative breast cancer progression through epigenetic activation of c-Myc.
    Yao B; Xing M; Zeng X; Zhang M; Zheng Q; Wang Z; Peng B; Qu S; Li L; Jin Y; Li H; Yuan H; Zhao Q; Ma C
    Clin Transl Med; 2024 Jul; 14(7):e1753. PubMed ID: 38967349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHD4-mediated loss of E-cadherin determines metastatic ability in triple-negative breast cancer cells.
    Luo CW; Wu CC; Chang SJ; Chang TM; Chen TY; Chai CY; Chang CL; Hou MF; Pan MR
    Exp Cell Res; 2018 Feb; 363(1):65-72. PubMed ID: 29305962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of triple negative breast cancer metastasis and invasiveness by novel drugs that target epithelial to mesenchymal transition.
    Garcia E; Luna I; Persad KL; Agopsowicz K; Jay DA; West FG; Hitt MM; Persad S
    Sci Rep; 2021 Jun; 11(1):11757. PubMed ID: 34083676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pomegranate peel extract inhibits expression of β-catenin, epithelial mesenchymal transition, and metastasis in triple negative breast cancer cells.
    Bagheri M; Fazli M; Saeednia S; Kor A; Ahmadiankia N
    Cell Mol Biol (Noisy-le-grand); 2018 May; 64(7):86-91. PubMed ID: 29974851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resveratrol enhances the sensitivity of FL118 in triple-negative breast cancer cell lines via suppressing epithelial to mesenchymal transition.
    Yar Saglam AS; Kayhan H; Alp E; Onen HI
    Mol Biol Rep; 2021 Jan; 48(1):475-489. PubMed ID: 33389483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DOT1L regulates MTDH-mediated angiogenesis in triple-negative breast cancer: intermediacy of NF-κB-HIF1α axis.
    Neeli PK; Sahoo S; Karnewar S; Singuru G; Pulipaka S; Annamaneni S; Kotamraju S
    FEBS J; 2023 Jan; 290(2):502-520. PubMed ID: 36017623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chrysin inhibits metastatic potential of human triple-negative breast cancer cells by modulating matrix metalloproteinase-10, epithelial to mesenchymal transition, and PI3K/Akt signaling pathway.
    Yang B; Huang J; Xiang T; Yin X; Luo X; Huang J; Luo F; Li H; Li H; Ren G
    J Appl Toxicol; 2014 Jan; 34(1):105-12. PubMed ID: 24122885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors.
    Su Y; Hopfinger NR; Nguyen TD; Pogash TJ; Santucci-Pereira J; Russo J
    J Exp Clin Cancer Res; 2018 Dec; 37(1):314. PubMed ID: 30547810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression.
    Li LX; Zhou JX; Calvet JP; Godwin AK; Jensen RA; Li X
    Cell Death Dis; 2018 Feb; 9(3):326. PubMed ID: 29487338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.